INBX
NASDAQ · Biotechnology
Inhibrx Biosciences Inc
$84.52
+4.24 (+5.28%)
Open$80.68
Previous Close$80.28
Day High$85.58
Day Low$79.47
52W High$155.29
52W Low$57.30
Volume—
Avg Volume384.3K
Market Cap1.18B
P/E Ratio—
EPS$-8.88
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
-78.5% upside
Current
$84.52
$84.52
Target
$18.13
$18.13
$12.39
$18.13 avg
$27.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.23M | 1.47M | 384.43M |
| Net Income | -133,097,692 | -142,570,724 | -115,444,062 |
| Profit Margin | -10,773.5% | -10,234.8% | -30.0% |
| EBITDA | -125,958,155 | -142,418,766 | -155,644,267 |
| Free Cash Flow | — | — | -85,235,104 |
| Rev Growth | -16.0% | -16.0% | -5.8% |
| Debt/Equity | 12.58 | 12.58 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |